Monsanto announces FY2014 results, good performance

October 12, 2014 |

In Missouri, Monsanto Company announced fiscal year 2014 results slightly above the high end of its guidance range on the strength of its global seeds and traits business, the biggest driver of growth for the year. This is the company’s fourth consecutive year of strong ongoing earnings growth. Executives noted that the balance of the company’s global business positions it well for continued growth and investment in fiscal year 2015 as the company executes on its plan to at least double ongoing EPS over the next five years.

Monsanto reported net sales of approximately $2.6 billion for the fourth quarter of fiscal year 2014. Net sales for the full fiscal year were approximately $15.9 billion, a seven percent increase over fiscal year 2013. Full-year net sales results were driven by the strength of the Seeds and Genomics segment, including a record year for the company’s soybean business.

Seeds and Genomics segment net sales were approximately $1.4 billion for the quarter. For the fiscal year, net sales for the Seeds and Genomics segment reached $10.7 billion. Agricultural Productivity segment net sales were $1.3 billion for the quarter. Net sales for the Agricultural Productivity segment for the fiscal year reached $5.1 billion.

Monsanto reported a net loss of $156 million in the fourth quarter of fiscal year 2014, compared with a reported net loss of $249 million in the same period last year. Net income attributable to Monsanto for fiscal year 2014 was approximately $2.7 billion, an increase over fiscal year 2013 net income attributable to Monsanto of $2.5 billion.

Monsanto said it “is positioned to deliver strong double-digit to mid-teens earnings growth in fiscal year 2015 despite continued industry headwinds and an increase in investments to unlock future growth. Monsanto expects to achieve EPS of $5.75 to $6.00 in fiscal year 2015. The company’s growth outlook is anchored on the continued strength of its core business, with the Seeds and Genomics segment setting the pace for overall EPS growth in fiscal year 2015. The company projects free cash flow in the range of $2 billion to $2.2 billion for fiscal year 2015.”

 

More on the story.

Print Friendly, PDF & Email

Tags: , ,

Category: Fuels

Thank you for visting the Digest.